CEO Ronny Hermansen comments:
"We are delighted to announce that our study "Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study" was accepted for publication in BMC Endocrine Disorders. Diabetes affects 11,3% and 6,2% of the population in the US and EU and it is of key importance that these patients receive diagnostics tools able to predict the probability of a diabetes disease course. The article's acceptance further underlines the strength of GA's research activities within the microbiome field and expand the areas for microbiota testing".

The publication summarizes the promising results for the use of microbiota as a tool for risk prediction of developing a diabetes disease course at an early stage. This new publication, written by researchers at GA, documents the strength of the research portfolio in Genetic Analysis and expands the use of the GA-map® testing platform into the Diabetes Type 2 disease area. According to WHO, about 96 million people aged 18 years or older have prediabetes in the US alone (38.0% of the adult US population). In Europe, about 40 million people aged 18 and above suffer from pre-diabetes. Tackling pre-diabetes before it develops into Type-2 diabetes is therefore highly beneficial for both patients and the health economy, underlining the need for and importance of accurate and validated microbiome diagnostics tools such as the GA-map®.

About the publication
The article "Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study" was accepted for publication in BMC Endocrine Disorders the 21. August 2023. In this study, the aim was to search for gut bacteria able to distinguish individuals in danger of developing Diabetes Type 2 disease from healthy. At least thirteen different bacteria were recognized as candidates for developing such a predictive test, representing differences in the abundance of short-chain fatty acid (SCFA) producing bacteria, and an increase in typical inflammation-associated or potentially pro-inflammatory or opportunistic bacteria, that may contribute to the variations in the microbiota separating Diabetes Type 2 patients from the healthy subjects.

For more information about the publication: https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-023-01432-0  (https://www.who.int/news-room/fact-sheets/detail/diabetes)

WHO 2023: https://www.who.int/news-room/fact-sheets/detail/diabetes

For more information, please contact:
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com